OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
Akinori Minato, Nobuki Furubayashi, Yujiro Nagata, et al.
Current Oncology (2024) Vol. 31, Iss. 2, pp. 862-871
Open Access | Times Cited: 8
Akinori Minato, Nobuki Furubayashi, Yujiro Nagata, et al.
Current Oncology (2024) Vol. 31, Iss. 2, pp. 862-871
Open Access | Times Cited: 8
Showing 8 citing articles:
Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON ‐2 Retrospective Experience
Mimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Cancer Medicine (2025) Vol. 14, Iss. 4
Open Access | Times Cited: 1
Mimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Cancer Medicine (2025) Vol. 14, Iss. 4
Open Access | Times Cited: 1
Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence
Mohammad Javad Khosravanian, Yousef Mirzaei, Ali Hussein Mer, et al.
Life Sciences (2024) Vol. 352, pp. 122910-122910
Closed Access | Times Cited: 6
Mohammad Javad Khosravanian, Yousef Mirzaei, Ali Hussein Mer, et al.
Life Sciences (2024) Vol. 352, pp. 122910-122910
Closed Access | Times Cited: 6
Antibody–drug conjugates in rare genitourinary tumors: review and perspectives
Andre Rashad Kydd, Md Shahid Sarwar, Saad Omar Atiq, et al.
Current Opinion in Oncology (2025)
Closed Access
Andre Rashad Kydd, Md Shahid Sarwar, Saad Omar Atiq, et al.
Current Opinion in Oncology (2025)
Closed Access
Current Advances in the Management of Nonurothelial Subtypes of Bladder Cancer
Evangelia Vlachou, Burles A. Johnson, Ezra Baraban, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 2
Evangelia Vlachou, Burles A. Johnson, Ezra Baraban, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 2
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior AvelumabVersusPembrolizumab Therapy
Akinori Minato, Nobuki Furubayashi, Toshihisa Tomoda, et al.
Anticancer Research (2024) Vol. 44, Iss. 8, pp. 3419-3426
Closed Access | Times Cited: 2
Akinori Minato, Nobuki Furubayashi, Toshihisa Tomoda, et al.
Anticancer Research (2024) Vol. 44, Iss. 8, pp. 3419-3426
Closed Access | Times Cited: 2
Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Yujiro Nagata, Akinori Minato, Hisami Aono, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10348-10348
Open Access | Times Cited: 1
Yujiro Nagata, Akinori Minato, Hisami Aono, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10348-10348
Open Access | Times Cited: 1
Clinical impact of a subtype of urothelial carcinoma in nonmuscle-invasive bladder cancer
Akinori Minato, Michiko Yoshii, Shiro Watanabe, et al.
Japanese Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 1
Akinori Minato, Michiko Yoshii, Shiro Watanabe, et al.
Japanese Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 1
Efficacy of avelumab maintenance therapy for advanced urothelial carcinoma with histologic subtype and divergent differentiation: a multicenter retrospective study conducted by the Uro-Oncology Group in Kyushu
Akinori Minato, Nobuki Furubayashi, Toshihisa Tomoda, et al.
Translational Andrology and Urology (2024) Vol. 13, Iss. 7, pp. 1118-1126
Open Access
Akinori Minato, Nobuki Furubayashi, Toshihisa Tomoda, et al.
Translational Andrology and Urology (2024) Vol. 13, Iss. 7, pp. 1118-1126
Open Access
Oncologic Outcomes of Patients with Immune Checkpoint Inhibitor Resistant Urothelial Carcinoma Treated with Enfortumab Vedotin and the Impact of Neutrophil-to-Lymphocyte Ratio and Dysgeusia on Overall Survival: A Retrospective Multicenter Cohort Study in Japan
Keita Nakane, Kazuki Taniguchi, Minori Nezasa, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2648-2648
Open Access
Keita Nakane, Kazuki Taniguchi, Minori Nezasa, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2648-2648
Open Access
